CagriSema Outperforms Wegovy in Latest Late-Stage Diabetes Trial
- 3 days ago
- 2 min read
Updated: 3 days ago
Novo Nordisk reported on February 2, 2026, that its next-generation experimental shot, CagriSema, successfully met primary objectives in a Phase 3 clinical trial. The study, known as REIMAGINE 2, involved over 2,700 adults with Type 2 diabetes who were also classified as overweight or obese.
CagriSema is a fixed-dose combination of semaglutide (the active ingredient in Wegovy and Ozempic) and cagrilintide, an analog that mimics the pancreatic hormone amylin. In the 68-week trial, participants receiving the 2.4-mg dose of CagriSema achieved a 1.91 percentage point reduction in HbA1c (a marker of long-term blood sugar), compared to a 1.76 point reduction for those on semaglutide alone.
The drug also demonstrated superior weight-loss capabilities. Participants on CagriSema lost 14.2% of their body weight, while those treated with Wegovy lost 10.2%. Despite these gains, the drug fell short of Novo’s internal benchmark of 25% weight loss, a target analysts described as "lofty".
The data strengthens Novo Nordisk’s position in its rivalry with Eli Lilly, whose drug Zepbound has become a global leader in the obesity market. While CagriSema’s current results appear numerically lower than some of Zepbound’s previous data, a high-stakes head-to-head trial comparing the two is expected to release results by the end of March 2026.
Novo Nordisk filed for FDA approval of CagriSema as a weight-loss treatment in December 2025. Martin Holst Lange, Novo’s chief scientific officer, stated that the drug could become the first amylin-based combination therapy on the market, offering a promising option for individuals managing both diabetes and weight loss. Side effects reported were typical of GLP-1 therapies, primarily involving gastrointestinal issues like nausea.
🔖 Sources
Keywords: CagriSema Outperforms Wegovy
CagriSema Outperforms Wegovy
Comments